Canaccord Genuity cuts Celldex Therapeutics target price to $43 from $68
CLDX•Canaccord Genuity cut its target price for Celldex Therapeutics to $43 from $68.
Related News

Intuit Inc.: Barclays cuts target price to $385 from $408
INTU•

Shenzhen three-power summit masks bilateral limits
UNG•

CervoMed CEO and President John Alam reports acquisition of $152,621.104 in common shares
CRVO•

Bruker Corporation: RBC initiates coverage with Sector Perform rating; price target $66
BRKR•

Anthropic's Australian data centre overwhelmingly opposed by residents
ANT•